Expanded evidence that the 31-gene expression profile test provides clinical utility for melanoma management in a multicenter study

References

• American Cancer Society. Cancer Facts & Figures 2019. 2019. 76. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2019.html.
   Google Scholar
• Freeman M, Laks S. Surveillance imaging for metastasis in high-risk melanoma: importance in individualized patient care and survivorship. Melanoma Manag. 2019;6:55. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582455/.
   Web of Science ®Google Scholar
• Ibrahim AM, Le May M, Bossé D, et al. Imaging intensity and survival outcomes in high-risk resected melanoma treated by systemic therapy at recurrence. Ann Surg Oncol. 2020;27(10):3683–3691.
   PubMed Web of Science ®Google Scholar
• Leiter U, Buettner PG, Eigentler TK, et al. Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit? Melanoma Res. 2010;20(3):240–246.
   PubMed Web of Science ®Google Scholar
• Lee AY, Droppelmann N, Panageas KS, et al. Patterns and timing of initial relapse in pathologic stage II melanoma patients. Ann Surg Oncol. 2017;24(4):939–946.
   PubMed Web of Science ®Google Scholar
• Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472–492.
   PubMed Web of Science ®Google Scholar
• Swetter SM, Thompson JA, Coit DG, et al. NCCN clinical practice guidelines in oncology. Cutaneous melanoma. Version 3.2020. USA: National Comprehensive Cancer Network (NCCN); 2020.
   Google Scholar
• Whiteman DC, Baade PD, Olsen CM. More people die from thin melanomas (1 mm) than from thick melanomas (>4 mm) in Queensland, Australia. J Invest Dermatol. 2015;135(4):1190–1193.
   PubMed Web of Science ®Google Scholar
• Howlader N;N. SEER cancer statistics review, 1975–2012. Bethesda, MD: National Cancer Institute; 2014. Available from: https://seer.cancer.gov/archive/csr/1975_2012/.
   Google Scholar
• Lo SN, Scolyer RA, Thompson JF. Long-term survival of patients with thin (T1) cutaneous melanomas: a breslow thickness cut point of 0.8 mm separates higher-risk and lower-risk tumors. Ann Surg Oncol. 2018;25(4):894–902.
   PubMed Web of Science ®Google Scholar
• Maurichi A, Miceli R, Camerini T, et al. Prediction of survival in patients with thin melanoma: results from a multi-institution study. J Clin Oncol. 2014;32(23):2479–2485.
   PubMed Web of Science ®Google Scholar
• Schuitevoerder D, Heath M, Cook RW, et al. Impact of gene expression profiling on decision-making in clinically node negative melanoma patients after surgical staging. J Drugs Dermatol. 2018;17(2):196–199.
   PubMed Web of Science ®Google Scholar
• Niebling MG, Haydu LE, Karim RZ, et al. Pathology review significantly affects diagnosis and treatment of melanoma patients: an analysis of 5011 patients treated at a melanoma treatment center. Ann Surg Oncol. 2014;21(7):2245–2251.
   PubMed Web of Science ®Google Scholar
• Patrawala S, Maley A, Greskovich C, et al. Discordance of histopathologic parameters in cutaneous melanoma: clinical implications. J Am Acad Dermatol. 2016;74(1):75–80.
   PubMed Web of Science ®Google Scholar
• Podlipnik S, Carrera C, Sánchez M, et al. Performance of diagnostic tests in an intensive follow-up protocol for patients with American joint committee on cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: a prospective cohort study. J Am Acad Dermatol. 2016;75(3):516–524.
   PubMed Web of Science ®Google Scholar
• Park TS, Phan GQ, Yang JC, et al. Routine computer tomography imaging for the detection of recurrences in high-risk melanoma patients. Ann Surg Oncol. 2017;24(4):947–951.
   PubMed Web of Science ®Google Scholar
• Livingstone E, Krajewski C, Eigentler TK, et al. Prospective evaluation of follow-up in melanoma patients in Germany – results of a multicentre and longitudinal study. Eur J Cancer. 2015;51(5):653–667.
   PubMed Web of Science ®Google Scholar
• Poklepovic A, Carvajal R. Prognostic value of low tumor burden in patients with melanoma. Oncology. 2018;32(9):e90–e96.
   PubMed Web of Science ®Google Scholar
• Joseph RW, Elassaiss-Schaap J, Kefford R, et al. Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab. Clin Cancer Res. 2018;24(20):4960–4967.
   PubMed Web of Science ®Google Scholar
• Giuliano AE, Connolly JL, Edge SB, et al. Breast Cancer-Major changes in the American joint committee on cancer eighth edition cancer staging manual: updates to the AJCC breast TNM staging system: the 8th edition. CA Cancer J Clin. 2017;67(4):290–303.
   PubMed Web of Science ®Google Scholar
• Wang M, Wu K, Zhang P, et al. The prognostic significance of the oncotype DX recurrence score in T1-2N1M0 estrogen receptor-positive HER2-Negative breast cancer based on the prognostic stage in the updated AJCC 8th edition. Ann Surg Oncol. 2019;26(5):1227–1235.
   PubMed Web of Science ®Google Scholar
• Gerami P, Cook RW, Russell MC, et al. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. J Am Acad Dermatol. 2015;72(5):780–785.e3.
   PubMed Web of Science ®Google Scholar
• Gerami P, Cook RW, Wilkinson J, et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res. 2015;21(1):175–183.
   PubMed Web of Science ®Google Scholar
• Grossman D, Kim CC, Hartman RI, et al. Prognostic gene expression profiling in melanoma: necessary steps to incorporate into clinical practice. Melanoma Manag. 2019;6(4):MMT32.
   PubMed Web of Science ®Google Scholar
• Cooperberg MR, Simko JP, Cowan JE, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol. 2013;31(11):1428–1434.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Swanson GP, Fisher G, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011;12(3):245–255.
   PubMed Web of Science ®Google Scholar
• Chudova D, Wilde JI, Wang ET, et al. Molecular classification of thyroid nodules using high-dimensionality genomic data. J Clin Endocrinol Metab. 2010;95(12):5296–5304.
   PubMed Web of Science ®Google Scholar
• Berger AC, Davidson RS, Poitras JK, et al. Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients. Curr Med Res Opin. 2016;32(9):1599–1604.
   PubMed Web of Science ®Google Scholar
• Dillon LD, Gadzia JE, Davidson RS, et al. Prospective, multicenter clinical impact evaluation of a 31-Gene expression profile test for management of melanoma patients. J of Skin. 2018;2(2):111–121.
   Google Scholar
• Scott AM, Dale PS, Conforti A, et al. Integration of a 31-Gene expression profile into clinical Decision-Making in the treatment of cutaneous melanoma. Am Surg. 2020;86(11):1561–1564.
   PubMed Web of Science ®Google Scholar
• Schuitevoerder D, Heath M, Massimino K, et al. Impact of genetic expression profile on decision-making in clinically node negative melanoma patients after surgical staging. Seattle: WA; 2017.
   Google Scholar
• Gaudi S, Zarandona JM, Raab SS, et al. Discrepancies in dermatopathology diagnoses: the role of second review policies and dermatopathology fellowship training. J Am Acad Dermatol. 2013;68(1):119–128.
   PubMed Web of Science ®Google Scholar
• Fayne RA, Macedo FI, Rodgers SE, et al. Evolving management of positive regional lymph nodes in melanoma: past, present and future directions. Oncol Rev. 2019;13(2):433. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902307/.
   PubMed Web of Science ®Google Scholar
• Gastman BR, Gerami P, Kurley SJ, et al. Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria. J Am Acad Dermatol. 2019;80(1):149–157.e4.
   PubMed Web of Science ®Google Scholar
• Trotter SC, Sroa N, Winkelmann RR, et al. A global review of melanoma follow-up guidelines. J Clin Aesthet Dermatol. 2013;6(9):18–26.
   PubMedGoogle Scholar